Catalyst
Slingshot members are tracking this event:
Phase III data for SMN-RX in Type II spinal muscular atrophy patients expected in the first half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BIIB | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 13, 2017
Occurred Source:
http://media.biogen.com/press-release/rare-and-genetic-diseases/new-data-show-spinraza-nusinersen-significantly-reduces-risk
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Smn-rx, Type Ii, Ionis-smn Rx, Spinal Muscular Atrophy, Nusinersen
